Fountain Healthcare Partners is a spin-out group from Elan Corporation’s (NYSE:ELN) New York based corporate venture capital group.

While at Elan, the team invested in over 25 life science companies, developing the next generation of products and technologies to address unmet medical needs.

Investments undertaken by the principals included:

	Acusphere, Inc (NASDAQ: ACUS) Drug delivery company with proprietary microsphere technology. IPO, October 2003. www.acusphere.com
	Allergy Therapeutics plc (AIM:AGY) Fully integrated pharmaceutical company that develops and sells allergy vaccines. IPO, October 2004. www.allergytherapeutics.com
	Atrix Laboratories Inc / QLT Inc. (NASDAQ:QLTI) Drug delivery company focused in oncology and dermatology. Acquired by QLT, June 2004. www.qltinc.com
	BG Medicine Developing novel molecular diagnostics based on proprietary biomarkers discovered using their proteomics platform. www.bg-medicine.com
	Chemgenex Pharmaceuticals Ltd (ASX:CXS) Biopharmaceutical company developing personalized oncology therapeutics. Acquired by AGT Biosciences, April 2004. www.chemgenex.com
	Depomed Inc (NASDAQ: DEPO) Specialty pharmaceutical company with proprietary gastro-retentive drug delivery platform. www.depomed.com
	Idun Pharmaceuticals Inc / Pfizer Inc (NYSE:PFE) Biopharmaceutical company focused on the discovery and development of therapies to control apoptosis. Acquired by Pfizer, April 2005. www.idun.com
	Imarx Therapeutics Inc (NASDAQ:IMRX) Biopharmaceutical company developing therapies for vascular clotting disorders. IPO NASDAQ, July 2007. www.imarx.com
	Sirna Therapeutics Inc / Merck Inc (NYSE:MRK) Biopharmaceutical company developing RNAi based therapies for various diseases, including age related macular degeneration (AMD), hepatitis C, dermatology and asthma. Acquired by Merck, Oct 2006. www.sirna.com
	Zealand Pharma A/S Biopharmaceutical company using a proprietary peptide modification technology platform to develop novel molecular entities for various indications. www.zp.dk

Fountain Healthcare Partners is supported by the European Union through the Competitiveness and Innovation Framework Programme (CIP).